Senior Managing Partner & CEO, Flagship Pioneering
Amicus logo.png


Chief Financial Officer, Amicus Therapeutics

William “Chip” Baird, has served for the last six years as the Chief Financial Officer of Amicus Therapeutics (Nasdaq: FOLD), a global commercial-stage biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.

Previously, Mr. Baird spent 10 years as the CFO of PTC Therapeutics (Nasdaq: PTCT), also in the rare disease space. In his roles as CFO, Mr. Baird has raised over $1.9 billion of capital through a variety of mechanisms, including private and public equity, convertible and venture debt, grant funding, and strategic collaborations. Mr. Baird has also helped lead successful M&A efforts for Amicus, acquiring three companies in the last four years.

Prior to his corporate roles at Amicus and PTC, Mr. Baird worked in strategy consulting for LEK Consulting in their life science group. Mr. Baird began his career in commercial banking at First Union National Bank.

Mr. Baird received a B.S. from Georgetown University's Edmund A. Walsh School of Foreign Service and an M.B.A. in finance from The Wharton School of the University of Pennsylvania.